Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant versus amiodarone for recent-onset atrial fibrillation in the emergency room
2012-000972-40Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Atrial fibrillation (AFib) comparing Vernakalant therapy with Amiodarone therapy (2 arms). Primary endpoint: Discharge from emergency room within 12 hours. Started May 2012; status: terminated.
02
Drugs
vernakalantamiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2012-000972-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000972-40.